The role of autophagy in Alzheimer’s disease

Qian Li1 and Miao Sun2*
1Department of cancer research, Weill Cornell Medical Center, USA
2Department of Neuroscience and Cell Biology, Robert Wood Johnson Medical School, Rutgers University, USA

Abstract
Autophagy is a key pathway to clear cellular abnormal protein aggregates, and is essential for protein homeostasis and neuronal health. Several studies have shown autophagy deficits may occur in early stage of Alzheimer’s disease (AD). Regarding to Alzheimer’s disease, autophagy itself plays an important role in generation and metabolism of β-amyloid (Aβ), assembling of tau and thus its dysfunction may lead to the progress or aggregate of AD. By considering all published evidences, autophagy may be considered as a new target for developing AD targeted drugs. So far, a number of mammalian target of rapamycin (mTOR)-dependent and independent autophagy modulators have been identified to have positive effects in AD treatment. In this review, we summarized the latest progress supporting the role for autophagy deficits in AD, and the potential therapeutic effects of autophagy modulators in AD.

Acronyms: AD: Alzheimer’s disease, Aβ: β-amyloid, mTOR: mammalian target of rapamycin, CMA: chaperone-mediated autophagy, ROS: reactive oxygen species, mTORC1: mammalian target of rapamycin complex 1, ULK: Unc-51-like kinase, LC3B: light chain 3 beta, PE: phosphatidylethanolamine, UVRAG: UV radiation resistance-associated gene protein, AMPK: AMP-activated protein kinase, DFCP-1: Double-FYVE Containing Protein 1, P13P: Phosphatidylinositol 3-Phosphate, AVs: autophagic vacuoles, SAD: sporadic AD, FAD: familial AD, apoE4: Apolipoprotein E4, APP: amyloid precursor protein, PS: presenilin, GSK-3: Glycogen synthase kinase-3, hsc 70: heat shock cognate protein of 70KD, LAMP-2A: lysosomal-associated membrane protein 2A, lys-hsc70: Lysosome-resident form of hsc70, APP-CTFs: amyloid precursor protein cleaved C-terminal fragment, AEL: autophagy-endosomal-lysosomal, PTK: Picrotoxin, UPS: ubiquitin-proteasome system, Nrf2: nuclear factor erythroid-2-related factor 2, PICALM: Phosphatidylinositol binding clathrin assembly protein, SNAREs: Soluble NSF Attachment protein Receptors

Introduction
AD, which is the most prevalent and common neurodegenerative disease for elder people, is characterized by deficiency in memory and cognitive functions. The predominant pathological hallmarks of AD are the generation of Aβ plaques in specific brain areas, formation of neurofibrillary tangles in neurons axons and progressive loss of dendrite synapses and the eventually neuron apoptosis [1,2]. Although the etiology and molecular mechanisms underlying these pathological changes are not completely elucidated, recent studies have indicated deficiencies in autophagy-lysosome pathway, which is an important system to eliminate misfolded proteins or damaged organelles, are likely to precede the formation of Aβ plaques or neurofibrillary tangles [3]. Until now, three kinds of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), have been identified in mammalian cells. Among them, macroautophagy is get best studied and considered most relevant to AD, CMA has also been indicated by some reports to play a role in AD. To make it simple, hereon we will refer macroautophagy as “autophagy”. In the present review, we will begin with the autophagy physiological machinery, evidence of autophagy malfunction in AD, relationship between autophagy dysfunction and AD-related pathology, and finally focus on the therapeutic potential of autophagy modulators.

Materials and methods
We used “Alzheimer’s disease” and “autophagy” as keywords to search PubMed and review the related papers.

Autophagy machinery
Autophagy biogenesis includes multiple stages: phagophore membrane isolation, phagophore elongation and engulf of random cytoplasmic content, autophagosome maturation and fusion with lysosome [4]. Generally, the activation of autophagy is largely depended on cellular starving condition [5,6], such as low amino acids or glucose concentration. However, recent studies have also proven autophagy could be stimulated by diverse factors, such as reactive oxygen species (ROS) [7], hypoxia impairments [8], subcellular organelle damages [9] and protein aggregation [10]. However, in all its regulators, the mammalian target of rapamycin complex 1 (mTORC1) has been studied most thoroughly and considered to play a key role in autophagy biogenesis.

In amino acid depletion environment, mTORC1 complex is in rest situation and distributed freely in cytoplasm. At that stage, mTORC1 complex cannot regulate autophagy initiation. However, in nutrition enrichment conditions, the lysosomal amino acid concentration will be largely increased, which will in turn activate v-ATPase on the lysosome membrane. v-ATPase is a lysosome membrane multimeric channel protein with a major function as ATPase and H+ channel, meanwhile,
it also functions as a sensor for lysosomal amino acid concentration. After sensing the increase of amino acid concentration, v-ATPase and its binding partner, Regulator, would both change their conformations and thus activate downstream signal molecule: RagA/B, by converting which conformation from GDP-bound to GTP-bound. Activated RagA/B will then recruit free mTORC1 onto lysosome membrane and facilitate another small GTPase, Rheb, to activate mTORC1 on lysosome membrane [11-13]. After mTORC1 activation, it will negatively control autophagy genesis by blocking Unc-51-like kinase (ULK) 1/2 complex, which is an important inducer for autophagy by regulating Beclin1-VPS34 complex [14]. On the other hand, activated ULKI/2 could also activate microtubule-associated protein 1 light chain 3 beta (LC3B) by phosphatidyethanolamine (PE) modification [15]. LC3 is important for phagophore elongation and autophagosome formation [16]. Furthermore, activated mTORC1 could also inhibit autophagosome fusion with lysosome by phosphorylating UV radiation resistance-associated gene protein (UVRAG) [17] and thus keeping autophagosome out of lysosome and blocking its maturation. Therefore, activated mTORC1 could inhibit autophagy bio-genesis at all required stages, and inhibition of mTOR pathway by either pharmacological compounds such as rapamycin or activation of AMP-activated protein kinase (AMPK) [18] could facilitate autophagy process.

**Autophagy in neuronal cells**

Autophagy is an essential pathway to maintain metabolism homeostatic in neurons [19]. Similar to other types of cells, with aging process, neuronal cell will also accumulate intracellular toxicant or damaged organelles such as mitochondria that must to be eliminated by autophagy to avoid potential cellular stress [20]. However, with its post-mitotic characters, neurons cannot dilute toxic substance by mitosis. So autophagy dependent protein/organelles clearance would be more important in neurons.

Neurons are characterized by their highly polarized axons and dendritic compartments. Through the connections between elongated axons and multi-directional dendrites, neurons could make to communicate to another neuron with distances many times longer than their cell soma and thus connect to each other’s from long distance with minimized cell number [21].

Autophagosomes in neurons are majorly formed at axonal tips and gradually matured when they are retrograde transporting along axons to cell somas [19]. There is another evidence indicated autophagosome may form in the middle part of axon in order to clear damaged mitochondria [22]. Furthermore, some research also indicated autophagosome axonal distal biogenesis might correlate with synaptic function as well [23]. The first step of autophagosome biogenesis at axon tip is recruiting Atg13 and Atg5 to Double-FYVE Containing Protein 1 (DFCP-1). DFCP-1 is a Phosphatidylinositol 3-Phosphate (PI3P) enriched, omega-shaped ER structure that serves as a platform for autophagosome biogenesis [24]. Then within 4–6 minutes, lipidated LC3 will be incorporated into the developing of autophagosome [25]. Autophagy induction is more efficient in younger neurons [26], as the expression amount of autophagy induction related proteins such as beclin-1, Atg5 and Atg7 will decline with age [27,28], which may potentially contributing to the late onset of many neurodegenerative diseases [29] including AD.

**Autophagy malfunction in AD**

There is substantial evidence that dysregulation of autophagy is actually occurred in both AD animal models and AD patients. As early as 1967, Suzuki had found a large amount of abnormal aggregated tau protein and subcellular vesicles accumulated in the dystrophic or swollen neurites in AD patient brains [30], but the identity of these vesicles was unclear until 2005, when Nixon’s group found immature autophagic vacuoles (AVs) accumulated in dystrophic neuritis in AD brains by using immunogold labeling and electron microscopy [31]. This is the first direct evidence showed autophagy deficiency was involved in AD. In the same year, similar results from PS-1/APP double transgenic mice [32] also showed AVs would be accumulated in neuronal dendrites and soma even before Aβ plaques appeared compared to age-matched controls. In addition to these direct ultramicroscopic results, several autophagy-related proteins have also been found down-regulated in AD process. For example, Rubinsztein reported decreased expression of some lysosomal protease in the early phase of AD patients [33]. A recent study has found down regulation of some autophagy-related genes: atg1, atg8a, and atg18 in aged Drosophila melanogaster compare with younger controls. Furthermore, the same study also found reduced autophagy activity and hyper-generation of Aβ were both considered to correlate with late-onset neuronal dysfunction and AD phenotype [34], indicating that reduction of autophagy-related gene expression with age may contribute to late onset AD.

Two types of AD has been identified to date: sporadic AD (SAD, also known as late-onset AD) and familial AD (FAD, also known as early-onset AD). Although little is known about the cause of late onset AD, it is widely accepted now that both genetic and environmental factors would contribute to this pathogenesis. Apolipoprotein E4 (apoE4), a major genetic risk factor for SAD, has been found can cause autophagy malfunction. Results from ApoE4 transgenic mice showed ApoE4 overexpression could lead to Aβ42 hyper-generation in lysosome, which could finally lead to hippocampus neurons death [35]. In addition, ApoE4 could potentiate Aβ peptides induced lysosomal contains leakage and cell apoptosis in Neuro-2a cells [36]. Taken together, these studies indicated ApoE4 and Aβ may work in concert to increase the susceptibility of lysosomal membranes disruption, release of lysosomal enzymes, and hence neuronal degeneration [36].

Regarding to FAD, at least three genes, amyloid precursor protein (APP), presenilin-1 and -2 (PS-1 and PS-2), have been identified as causative genes so far. FAD is caused by mutation in at least one of the three genes [37]. Research has found wildtype PS-1, but not mutation forms, is crucial for acidification of lysosome by regulating distribution of v-ATPase, and thus contributes to autophagy degradation in a gamma-secretase independent way [38]. Meanwhile, hyper-activation of Glycogen synthase kinase-3 (GSK-3), which is also a high-risk factor for AD, could interfere lysosome acidification via similar mechanism as PS-1 [39]. These investigations suggested that autophagy malfunction is involved in FAD, while the mechanism(s) is still not clear.

Proper formation and degradation of autophagosome is critical for normal autophagic flux. In healthy neurons, low basal autophagic activity was detected because of the quick subsequent degradation of autophagosome by lysosome. In hippocampus neurons of AD mice, abnormal accumulation of immature AVs in axon was observed before synaptic and neuronal loss [40]. However, as either autophagosome axonal trafficking deficiency or insufficient lysosome acidification could cause AVs accumulation in axon, the actual mechanisms underlying autophagy dysfunction in AD is still need further investigate. It is also a debate whether dysfunction of autophagy is the cause or result of AD. Reports to date usually show some controversies [41-43]. Many factors may lead to these differences, such as different animal models, cellular models, and experimental paradigms. Also, the different model systems...
Aβ has also been found to be degraded by autophagy through the facilitation of APP [57] as well as all besides those well-known Aβ degradation enzymes [56]. Autophagy of all, autophagy is believed to be another major Aβ clearance pathway among autophagy, Aβ, and tau, which may contribute to the progress of AD. Emerging evidence has demonstrated complicated interactions considered as two major neuro-pathological changes in AD patient’s brain. Autophagy dysfunction and AD-related pathology

To date, Aβ plaques and neurofibrillary tangles are still be accumulate immature autophagysomes in axons. Another autophagy form is CMA. CMA is distinct from macroautophagy as CMA degradation pathway will accurately degrade certain proteins without engulf process and most of its degradation target proteins would be cytoplasm soluble proteins. This selective degradation pathway also contributes to maintenance of cellular homeostasis particularly under stress conditions together with other types of autophagy [44-47]. In the process of CMA mediated degradation, targeted protein will first be recognized and bind by a cytosolic chaperone, heat shock cognate protein of 70KD (hsc 70). Most of hsc 70 targeting proteins share a reserved KFERQ sequence [48]. After binding with cytoplasmic hsc70, the target proteins will be unfolded and delivered onto lysosome membrane. At lysosome membrane, lysosomal-associated membrane protein 2A (LAMP-2A) will form a transient multimeric channel to allow target proteins to translocate through lysosome membrane. Lysosome-resident form of hsc70 (lys-hsc70) in lysosome luminal side will also assist this process [49-52]. It has been considered that the number of lys-hsc70 positive lysosome would decide the speed of CMA mediated degradation under physiology condition.

Similar to macroautophagy, CMA is also considered to be related with neurodegeneration diseases such as AD and PD. It has been found CMA plays an important role in both Tau tangles formation and Aβ peptides generation and its activity is impaired in aged cells [53]. It has been found although Tau protein contains CMA recognizing motif in its sequence, trace amount of wild type Tau is indeed degraded by CMA. Generally, for totally degradation, Tau will be cleaved in cytoplasm firstly, and then the C-terminal part translocate into lysosome luminal for second and third cleavage [54]. Either autophagy or CMA process will both assist C-ter Tau get through lysosomal membrane. However, in certain Tau mutations, the first cleavage may happen in wrong amino acid position. After this cleavage, although remaining C-ter truncated Tau could still be recognized by hsc70 and recruited onto lysosome membrane, it cannot translocate into lysosome luminal efficiently, and thus resulting in accumulation of truncated Tau on lysosome membrane. Those undigested truncated Tau will then form oligomeric structures on the lysosomal membrane, gradually disrupt lysosomal membrane and finally cause leakage of lysosomal enzymes [53].

Another recent study has found APP also has KFERQ motif which could be recognized by hsc70. Deletion of this sequence will block APP degradation in lysosome and correspondently increase its secretase cleavage products. However, APP could still bind to hsc70 even without this KFERQ motif [55].

### Autophagy dysfunction and AD-related pathology

To date, Aβ plaques and neurofibrillary tangles are still be considered as two major neuro-pathological changes in AD patient’s brain. Emerging evidence has demonstrated complicated interactions among autophagy, Aβ, and tau, which may contribute to the progress of AD.

Autophagy plays an important role in the metabolism of Aβ. First of all, autophagy is believed to be another major Aβ clearance pathway besides those well-known Aβ degradation enzymes [56]. Autophagy facilitates the degradation and clearance of APP [57] as well as all APP cleavage products including Aβ [47,58], and APP-CTFs (amyloid precursor protein cleaved C-terminal fragment) [59]. In microglia, Aβ has also been found to be degraded by autophagy through the autophagy receptor optineurin [60].

Secondly, autophagy-lysosome degradation system, which is considered important for Aβ degradation under multiple physiological conditions, has been demonstrated to be a novel way for Aβ production under pathological condition or in aging process [32]. Although Aβ is thought to be produced in endoplasmic reticulum, lysosome, and Golgi apparatus, emerging studies have provided evidence that Aβ generation may also happened in autophagic vacuoles [61]. Thus, accumulated immature autophagic vacuoles found in AD brains and in APP/PS1 transgenic mice may present a novel source for Aβ generation [31]. Immunohistochemistry staining also showed Aβ42 were existed in AEL (autophagy-endosomal-lysosomal) vesicles in Drosophila neurons [62]. Another study applied on neuron showed that although APP and its processing enzyme BACE1 should be separated into distinct vesicles under normal condition, they showed strong co-localization and co-trafficking into autophagy-lysosome pathways under glycine/NMDA-receptor agonist /K+ or GABA antagonist Picrotoxin (PTX) stimulations [63]. This result indicated under some certain pathological conditions, the convergence of APP and BACE1 in autophagosomes may perform as novel place for Aβ generation.

Third, autophagy is also involved in the secretion of Aβ. Recent findings support that autophagy may responsible for extracellular released Aβ. Measurement of extracellular Aβ in autophagy-deficient mice may perform as another effective degradation route for Tau. A number of studies have demonstrated that dysfunction of autophagy-lysosome system leads to the formation of tau oligomers and insoluble aggregates, meanwhile activates autophagy could alleviate this aggregation [67,68]. Moreover, autophagy may affect Tau phosphorylation status. Hyperphosphorylated tau was found to be accumulated in brains of tauopathies deficient mice [69], and this Hyperphosphorylated-tau accumulation will be largely reduced after autophagy was restored. Researchers have found autophagic degradation of tau is regulated by nuclear factor erythroid-2-related factor 2 (Nrf2)-mediated activation of the autophagy receptor NDP52 [70]. Furthermore, Phosphatidylinositol binding clathrin assembly protein (PICALM, also known as CALM) could also regulate Tau degradation by modulating SNAREs (Soluble NSF Attachment protein Receptors) endosytosis, which is critical for tau autophagy clearance [71]. On the other hand, hyperphosphorylation of tau may result in autophagy dysfunction [72,73]. Tau is well-identified to facilitate the assembly and stabilization of microtubule, which is critical for autophagosome retrograde trafficking and maturation to fuse with lysosome. On contrast, hyperphosphorylated tau could lead to the instability and disassembly of microtubule cytoskeleton, which could subsequently inhibit autophagosome retrograde trafficking and thus accumulate immature autophagosomes in axons.

Axonal transport is an essential process required to maintain neuronal homeostasis. Impaired axonal transport can lead to axonopathy.
degeneration and has been found in many neurodegenerative diseases including AD. In mammalian cells, newly formed autophagosomes move along with microtubule tracks [74] and during this process, autophagosomes engulf long-lived protein, misfolded protein or damaged organelles such as mitochondria, subsequently degrade them after fused with lysosome. Deficits in axonal transport usually result in accumulation of large amounts of autophagosome. Axonal dystrophic neurites arising from neurofibrillary tangles could be easily detected in hippocampus CA3 and CA1 regions [75].

Years of pathological examination in AD brains have yielded many descriptions of abnormal axonal transport in both early and late phase of AD [76]. Meanwhile, the phosphorylated tau level affects axonal transport and degradation [77]. These data supported that abnormal protein aggregates disrupt axons, thereby autophagosomes couldn’t transport to cytoplasm and thus failed to fuse with lysosomes. In contrast to this, some other studies gave opposite viewpoints that lysosomal protease abnormalities are the causative factor of axonal degeneration [78]. However, the mechanism(s) underlying this transport disruption isn’t clear.

Concluding remarks and future perspectives

Although the etiology of AD remains unclear, and many factors including genetic mutation, environmental factors, imbalance of energy metabolism and heavy metal ion [79,80] seem to contribute to the etiology of AD, emerging advances regarding to autophagy could be critical for designing new experiments with appropriate drug doses in any future clinical trials for AD. As well as brain pharmacokinetics of autophagy modulators will be demonstrated to have positive effects in AD animal models and patients. However, a more thorough understanding of autophagy malfunction in AD, as well as brain pharmacokinetics of autophagy modulators will be critical for designing new experiments with appropriate drug doses in any future clinical trials for AD.

References

1. Ingelsson M, Fukumoto H, Newell KL, Crowden JH, Hedley-Whyte ET, et al. (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62: 925-931. [Crossref]
2. Li Q, Liu Y, Sun M (2016) Autophagy and Alzheimer’s Disease. Cellular and molecular neurobiology 1-12. [Crossref]
3. Correia SC, Resende R, Moreira PL, Pereira CM (2015) Alzheimer’s disease-related misfolded proteins and dysfunctional organelles on autophagy menu. DNA Cell Biol 34: 261-273. [Crossref]
4. Lee KM, Hwang SK, Lee JA (2013) Neuronal autophagy and neurodevelopmental disorders. Exp Neurobiol 22: 133-142. [Crossref]
5. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, et al. (2004) The role of autophagy during the early neonatal starvation period. Nature 432: 1032-1036. [Crossref]
6. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y (2004) In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 15: 1101-1111. [Crossref]
7. Schez-Shoval R, Shvets E, Fass E, Shorer H, Gil L, et al. (2007) Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26: 1749-1760. [Crossref]
8. Mazure NM, Pouyssegur J (2010) Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 22: 177-180. [Crossref]
9. Song Z, Zhao D, Yang L (2013) Molecular mechanisms of neurodegeneration mediated by dysfunctional subcellular organelles in transmissible spongiform encephalopathies. Acta Biochim Biophys Sin (Shanghai) 45: 452-464. [Crossref]
10. Liu C, Gao Y, Barrett J, Ho B (2010) Autophagy and protein aggregation after brain ischemia. J Neurochem 115: 68-78. [Crossref]
11. Zouc R, Ban-Peled L, Efeyan A, Wang S, Sanacik Y, et al. (2011) mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H+(ATPase. Science 334: 678-683. [Crossref]
12. Jewell JL, Russell RC, Guan KL (2013) Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 14: 133-139. [Crossref]
13. Yadav RB, Burgos P, Parker AW, Iadevaia V, Proud CG, et al. (2013) mTOR direct interactions with Rheb-GTPase and raptor: sub-cellular localization using fluorescence lifetime imaging. BMC Cell Biol 14: 3. [Crossref]
14. Russell RC, Tian Y, Yuan H, Park HW, Chang YY, et al. (2013)ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol 15: 741-750. [Crossref]
15. Fujita N, Itoh T, Omori H, Fukuda M, Noda T, et al. (2008) The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell 19: 2092-2100. [Crossref]
16. Bernard A, Klionsky DJ (2014) Defining the membrane precursor supporting the nucleation of the phagophore. Autophagy 10: 1-2. [Crossref]
17. Kim YM, Jung CH, Seo M, Kim EK, Park JM, et al. (2015) mTORC1 phosphorylates UVRAG to negatively regulate autophagosome and endosome maturation. Mol Cell 57: 207-218. [Crossref]
18. Wu T, Wang MC, Jing L, Liu ZY, Guo H, et al. (2015) Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Devel Ther 9: 6421-6431. [Crossref]
19. Maday S, Wallace KE, Holzbaur EL (2012) Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J Cell Biol 196: 407-417. [Crossref]
20. Morisho G, Madeo F, Kroemer G (2011) Autophagy for tissue homeostasis and neuroprotection. Curr Opin Cell Biol 23: 198-206. [Crossref]
21. Bullmore E, Sporns O (2012) The economy of brain network organization. Nat Rev Neurosci 13: 336-349. [Crossref]
22. Ashrafi G, Schlehe JS, LaVoie MJ, Schwarz TL (2014) Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J Cell Biol 206: 655-670. [Crossref]
23. Wang T, Martin S, Papadopulos A, Harper CB, Mavlyutov TA, et al. (2015) Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type a. J Neurosci 35: 6179-6194. [Crossref]
24. Maday S, Holzbaur EL (2014) Autophagosome biosynthesis in primary neurons follows an ordered and spatially regulated pathway. Dev Cell 30: 71-85. [Crossref]
25. Maday S, Holzbaur EL (2012) Autophagosome assembly and cargo capture in the distal axon. Autophagy 8: 858-860. [Crossref]
26. Boland B, Kumar A, Lee S, Platt FM, Wiegell J, et al. (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci 28: 6926-6937. [Crossref]
27. Lipinski MM, Zheng B, Lu T, Yan Z, Py BF, et al. (2010) Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer’s disease. Proc Natl Acad Sci U S A 107: 14164-14169. [Crossref]
28. Shibata M, Lu T, Furuya T, Degterev A, Mizushima N, et al. (2006) Regulation of intracellular accumulation of mutant Huntingtin in Beclin 1. J Biol Chem 281: 14474-14485. [Crossref]
29. Rabinstein DC, Morisho G, Kroemer G (2011) Autophagy and aging. Cell 146: 682-695. [Crossref]
30. Suzuki K, Terry RD (1967) Fine structural localization of acid phosphatase in senile plaques in Alzheimer’s presentiment disease. Acta Neuropathol 8: 276-284. [Crossref]
31. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, et al. (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 64: 113-122. [Crossref]
32. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, et al. (2005) Macrophagy: a novel beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol 171: 87-98. [Crossref]
79. Yu J, Sun M, Chen Z, Lu J, Liu Y, et al. (2010) Magnesium modulates amyloid-beta protein precursor trafficking and processing. *J Alzheimers Dis* 20: 1091-1106. [Crossref]

80. Li M, Sun M, Liu Y, Yu J, Yang H, et al. (2010) Copper downregulates neprilysin activity through modulation of neprilysin degradation. *J Alzheimers Dis* 19: 161-169. [Crossref]